MedPath

Biofeedback for CHAMPS

Not Applicable
Completed
Conditions
Stress
Disordered Eating
Interventions
Behavioral: Heart rate variability biofeedback
Registration Number
NCT04921228
Lead Sponsor
Villanova University
Brief Summary

As a result of the COVID-19 pandemic, the degree of burnout and consequential negative psychological effects experienced by healthcare providers has been substantially exacerbated. Heart rate variability (HRV) biofeedback has long been used to assist with a wide variety of stress-related concerns. Building on evidence that HRV biofeedback has the potential to improve wellbeing, the purpose of this study is to pilot test and determine the feasibility of implementing a digital HRV biofeedback tool to improve disordered eating, mindful self-care (i.e., self-compassion, body appreciation, etc.), and perceived stress in healthcare providers. In addition to assessing acceptability and feasibility of the HRV biofeedback tool, the investigators will aim to establish 'proof-of-concept' for a conceptual model consisting of potential psychological constructs underlying the mechanisms of change for the intervention-namely mind-body awareness (i.e., interoception) and resilience. Our primary recruitment pool will include healthcare providers who reported elevated eating distress as a participant in an ongoing observational study of the health effects of theCOVID-19 pandemic on essential workers (CHAMPS).

Detailed Description

Previous research suggests healthcare professionals may be a population at high-risk for disordered eating. As a result of the COVID-19 pandemic, the degree of burnout and consequential negative psychological effects experienced by healthcare providers has been substantially exacerbated. In fact, in an ongoing study of essential workers during the COVID-19 pandemic, the investigators found over a third of nursing professionals endorsed clinically significant disordered eating. With the clear evidence showing a psychological toll of the COVID-19 pandemic among healthcare workers globally, addressing their wellbeing with feasible at-home interventions is a priority.

Heart rate variability (HRV) biofeedback has long been used to assist with a wide variety of stress-related concerns, including depression and anxiety (Lehrer et al., 2020), both conditions that commonly co-occur with disordered eating. Research suggests interoception (i.e., the capacity to detect and respond to signals from the body), is disrupted in those with eating disorders (Martin et al., 2019). While there is relatively sparse evidence on the relationship between HRV and interoception (Pinna \& Edwards, 2020), it is theoretically plausible that superior interoception would predict improved vagal tone (i.e., parasympathetic activity) as measured by HRV. Moreover, data on HRV and disordered eating is mixed, and poorly understood (Watford et al., 2020). The present research seeks to begin addressing this gap in knowledge through a pilot feasibility study designed to initiate proof-of-concept for the development of a conceptual model.

Specifically, the study aims to:

1. assess the feasibility of implementing a digitally based HRV biofeedback protocol

2. assess the acceptability and usability of HRV biofeedback in healthcare providers with elevated disordered eating

3. examine signals of efficacy to begin building a conceptual model of the potential mechanisms underlying change in outcomes

4. test whether there is a relationship between intervention engagement/adherence and change in outcomes.

Participants will be recruited from a registry of healthcare providers enrolled in an ongoing study of the health effects of working during the COVID-19 pandemic (unless recruitment goals are not met using this method). This single arm feasibility pilot will provide the data to help determine the acceptability of using a smartphone based HRV biofeedback training tool as an intervention for this population and guide the refinement of the conceptual model being developed. By establishing feasibility and proof-of-concept, the study will build upon a limited body of work and establish an important first step towards understanding intervention dosing and signals of efficacy for aiding with disordered eating and related mind-body factors in this population.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  1. Age 18 years or older
  2. Ability to speak and read English
  3. Previously enrolled in the protocol titled "COVID-19 CHAMPS study" (IRB-FY2020-215) (ClinicalTrials.gov: NCT04370821)
  4. Willing to be contacted about other studies (i.e., CHAMPS study participants who agreed to be contacted about future research opportunities)
  5. Works in the healthcare professions
  6. Elevated eating distress as indicated by Loss of Control Eating scores above the median of 2 in this cohort.
  7. Owns either an iPhone or Android smartphone for running the app involved in the intervention
Read More
Exclusion Criteria
  1. History of a heart transplant or a pacemaker.
  2. Uncontrolled kidney disease
  3. Uncontrolled diabetes
  4. Heart failure
  5. COPD (Chronic Obstructive Pulmonary Disease)
  6. Use of tricyclic antidepressant (e.g., nortriptyline, amitriptyline) above 75 mgs daily
  7. Use of illicit stimulants (e.g., cocaine) or narcotic drugs
  8. Inability to perform study protocol (self selected)
  9. Current use of HRV biofeedback training
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Heart rate variability biofeedbackHeart rate variability biofeedbackHeart rate variability biofeedback training will be administered via a smartphone app (Optimal HRV) that reads the participants' pulse rate through a Bluetooth connected photoplethysmography (PPG) sensor attached to the finger or thumb.
Primary Outcome Measures
NameTimeMethod
Engagement/adherence to protocolBegins as soon the participant begins biofeedback training through the end of HRV biofeedback intervention - 8 weeks total

Measured by calculating: a) the proportion of the fully enrolled participants meeting pre-determined study engagement criteria (i.e., =\>28 days of the 42 where a minimum of 10 minutes of biofeedback is completed), and b) the total number of minutes of biofeedback training logged over the 8-week protocol.

This will assess intervention's acceptability and serve as a measure of participant engagement

\*There is a change in this section from what was originally posted. The PI noticed a discrepancy between Aims stated on the funded grant proposal and ClinicalTrials.gov record therefore we fixed ClinicalTrials.gov so that it reflected the grant's Aims statement.

Full enrollment:Participant receipt of study device and initial study visit - Week 2

Measured by calculating the proportion of the people who pre-enroll in the study who complete their first study visit that introduces the use of the HRV biofeedback app.

This will assess feasibility to fully enroll participants in the HRV biofeedback protocol once they have agreed to participate and receive the device.

Attrition/Drop outTraining visit through final check-in and post-intervention assessments (approximately 10 weeks of study involvement

Measured by calculating the proportion of fully enrolled participants who complete the pilot study.

This is to assess feasibility of program implementation.

Usabilitypost-intervention assessment (approximately 8 weeks after HRV biofeedback training visit)

Measured by calculating: a) the proportion of participants who rate HRV biofeedback practice as at least "moderately useful" (=\>3 on a 1-5 Likert scale), and b) the proportion of participants who are at least "likely" (=\>4 on a 1-5 Likert scale) to continue with their HRV biofeedback once the study ends.

This is to assess the usability of HRV biofeedback in this population.

Pre-enrollment:Consent interview/Baseline assessment - Week 0

Measured by calculating the proportion of the people contacted who initially agree to participate in the study, defined as individuals who complete the baseline assessment following consent.

This will assess feasibility to establish interest in HRV biofeedback among eligible participants from the CHAMPS registry.

Secondary Outcome Measures
NameTimeMethod
Variation in resiliencebaseline, midpoint (1 month after HRV biofeedback training visit), post intervention (2 months after HRV biofeedback training visit)

Measured using the Sense of Coherence Scale Revised (SOC-R Range: depends on dimension, higher scores indicate better outcome)

Variation in disordered eating attitudes and behaviorsbaseline, midpoint (1 month after HRV biofeedback training visit), post intervention (2 months after HRV biofeedback training visit

Measured using the Loss of Control Eating Scale-7 item Brief (LOCES-Brief Range: 1-5, higher scores indicate worse outcome)

Variation in interoceptionbaseline, midpoint (1 month after HRV biofeedback training visit), post intervention (2 months after HRV biofeedback training visit)

Measured using the Hunger and Satiety subscale of the Intuitive Eating Scale-2 (IES-2 Range: 1-5, higher scores indicate better outcome)

Variation in HRVbaseline, post intervention (approximately 10 weeks after baseline assessment)

Measured using the average daily RMSSD pre and post HRV biofeedback training

Variation in perceived stressbaseline, midpoint (1 month after HRV biofeedback training visit), post intervention (2 months after HRV biofeedback training visit)

Measured using the Perceived Stress Scale, (PSS Range: 0-40, higher scores indicate worse outcome)

Variation in mindful self-carebaseline, midpoint (1 month after HRV biofeedback training visit), post intervention (2 months after HRV biofeedback training visit)

Measured using the Mindful Self-Care Scale, (MSCS Range: depends on dimension, higher scores indicate better outcome)

Variation in body appreciationbaseline, midpoint (1 month after HRV biofeedback training visit), post intervention (2 months after HRV biofeedback training visit)

Measured using the Body Appreciation Scale-2 (BAS-2 Range: 1-5, higher scores indicate better outcome)

Trial Locations

Locations (1)

Villanova University

🇺🇸

Villanova, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath